Continuation of the NIDDK Gastroparesis Consortium
Continuation of the NIDDK Gastroparesis Consortium
批准号:
8114332
负责人:
Richard Warwick McCallum
金额:
$41.51万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2016-08-31
关键词:
Abdominal PainAddressAdverse effectsAffectAntiemeticsAssesChronicClinicalClinical DataClinical ResearchDiagnosisDiseaseDomperidoneDopamine AntagonistsDoseDouble-Blind MethodEtiologyFDA approvedFailureGastric EmptyingGastroparesisGoalsKnowledgeLeadMalnutritionMethodsMetoclopramideMulticenter StudiesNational Institute of Diabetes and Digestive and Kidney DiseasesNausea and VomitingNutritional SupportOutcomePathogenesisPatientsPhasePhysiciansPropertyProtocols documentationPublic HealthQuality of lifeRegistriesResearchRiskSafetySatiationSeriesStomachTherapy Clinical TrialsTimeTreatment EfficacyWomanclinical carediabeticfollow-upimprovedmeetingsnovel therapeuticsplacebo controlled studyrandomized trialresponse
中文摘要
描述(申请人提供):胃轻瘫(GP)是一种胃动力功能障碍,特征是胃排空延迟,经常与慢性恶心和呕吐、早饱、餐后饱、腹痛和营养不良有关,可能需要营养支持。全科医生对生活质量有毁灭性的影响,主要影响年轻女性。在过去的5年里,胃瘫临床研究联盟(GpCRC)做出了一系列重要的贡献,以提高我们对这种疾病的理解,这些观察结果促进了帮助我们的患者及其医生的目标,以及实现改善胃瘫管理的目标。因此,我们为这项应用提出了以下具体目标:#1:完成GpCRC发起的正在进行和获得批准的研究;#2:维护、扩展和完善GP注册,并通过对GPR临床数据和生物样本的进一步深入分析,解决与GP患者的发病机制、并发症和临床结果相关的重要问题;#3:开展新的胃轻瘫多中心研究,调查病因、发病机制、诊断和治疗方案。TTUHSC正在提议一项为期4个月的双盲、“失败时间”安慰剂对照试验(第1阶段)和为期8个月的“最佳临床护理”随访(第2阶段),以评估多潘立酮治疗胃瘫的疗效和安全性。这项多中心随机试验的主要目标是:1)记录多潘立酮对GP患者的疗效;2)比较多潘立酮对糖尿病患者和特发性病因的疗效;3)调查最佳剂量;4)探索预测最佳临床反应的人口统计学和临床因素;5)评估安全性。与FDA批准的促动力药甲氧氯普胺不同,甲氧氯普胺也是一种多巴胺拮抗剂,具有止吐和促动力特性,多潘立酮长期服用具有极好的安全性。由于多潘立酮在美国的可获得性非常有限(通过FDA协议),许多与其疗效、治疗剂量和副作用有关的问题仍未得到回答。因此,我们提出了这项研究来解决这些问题。
与公共卫生的相关性:这项研究强调了胃轻瘫(GP)的公共卫生意义,包括:需要开发有效的GP管理方法,需要确定哪些患者有可能进展为更严重的GP,需要确定导致GP的关键细胞变化,以及启动几个可能直接影响GP患者生活质量的新型治疗试验,这些试验可能会为医生治疗这些患者提供新的知识。
英文摘要
DESCRIPTION (provided by applicant): Gastroparesis (GP) is a disorder of gastric motilityfunction characterized by a delay in gastric emptying, frequently associated with chronic nausea and vomiting, early satiety, postprandial fullness, abdominal pain, and malnutrition that may require nutritional support. GP has a devastating impact on quality of life and predominantly affects younger women. In the past 5 years, the Gastroparesis Clinical Research Consortium (GpCRC) has made a series of important contributions to improve our understanding of this disorder and these observations have advenced the goals of helping our patients and their physicians as well as meeting the goals to improve the management of gastroparesis. We therefore propose the following specific aims for this application: # 1: To complete the ongoing and approved studies initiated by the GpCRC; # 2: To maintain, expand, and refine the GP Registry, and to address important questions related to the pathogenesis, complications and clinical outcome in GP patients by further in-depth analysis of GpR clinical data and biosamples; # 3: To conduct new multicenter studies of gastroparesis investigating the etiology, pathogenesis, diagnosis, and treatment options. TTUHSC is proposing a double-blind, "time- to- failure" placebo controlled trial (phase 1) of 4 months duration with "a best clinical care" follow up (phase 2) of 8 months duration study to evaluate the efficacy and safety of domperidone in gastroparesis. The principal objectives of this multicenter, randomized trial are to:1) Document the efficacy of domperidone in GP patients; 2) Compare domperidone's efficacy in diabetics vs. idiopathic etiologies;3) Investigate the optimal dose or doses; 4) Explore the demographic and clinical factors which predict the best clinical response; 5) Asses safety. Unlike the FDA approved prokinetic agent, metoclopramide, which is also a dopamine antagonist, with antiemetic and prokinetic properties, domperidone has an exellent safety profile for long- term administration. Due to the very restricted accessibility of domperidone in US (through the FDA protocol) many questions related to its efficacy, therapeutic dosing and side effects still remain unanswered. Therefore, we have proposed this study to resolve these questions.
PUBLIC HEALTH RELEVANCE: This research underscores the public health significance of gastroparesis (GP) including; the need to develop effective methods for management of GP, the need to identify patients who are at risk of progression to more severe GP, to identify the key cellular changes that lead to GP, and to initiate several novel, therapeutic trials that have the potential to directly influence the quality of life of patients with GP and also in turn provide new knowledge for physicians to treat these patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis
-
批准号:10474230
-
项目类别:
-
资助金额:$13.33万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis
-
批准号:10319436
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
Continuation of the NIDDK Gastroparesis Consortium
-
批准号:8545804
-
项目类别:
-
资助金额:$38.68万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
Continuation of the NIDDK Gastroparesis Consortium
-
批准号:8327165
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
Continuation of the NIDDK Gastroparesis Consortium
-
批准号:8730618
-
项目类别:
-
资助金额:$46.63万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric Participants with Symptoms of Gastroparesis
-
批准号:10842169
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis
-
批准号:9357569
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis
-
批准号:10021025
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2008
-
负责人:Richard Warwick McCallum
-
依托单位:
海外基金